The relationship between the expression of nm23, a putative metastasis-suppressor gene and prognosis was determined for 88 patients with sarcomas. Immunohistochemistry using immunopurified anti-nm23 peptide antibodies was performed and the results of each case graded according to the degree of staining. Univariate and multivariate analyses were carried out to determine the prognostic significance of nm23 staining for sarcoma patients. Expression of nm23 was found to increase in line with metastatic potential in many cases but this did not reach significance for the study as a whole. However, the possibility of nm23 loss occurring in association with metastasis cannot be ruled out in some more aggressive sarcomas, as was demonstrated for six patients with low-scoring, unclassified and synovial sarcomas that had metastasized. The time to metastasis was longer for patients with grade 3 sarcomas (50-75% of tumour cells staining) than similar patients in other staining groups. These results suggest that expression of nm23 genes in sarcomas is variable and has no value as a prognostic indicator for these mesenchymal tumours.
Soft tissue sarcomas are rare tumours occurring at different sites of the body and varying greatly in their degree of aggressiveness. Although a number of prognostic factors are associated with the metastatic potential of these tumours, e.g. tumour size, site, depth and histological type, tumour grade remains to be the single most reliable prognostic indicator (Russell et al, 1977; Hajdu, 1979; Robinson et al, 1990) . Approximately 60% of sarcomas are high grade and approximately half of these will metastasize, predominately to the lung. To provide therapy appropriate to prognosis and tumour responsiveness, precise diagnostic and predictive markers would be an advantage. New functionally based tests are therefore required to assist in the determination of the potential aggressive nature of sarcomas and thus the value to the patient of any adjuvant therapy.
nm23 is a putative metastasis-suppressor gene originally identified because of its down-regulation in highly metastatic variants of a murine melanoma cell line (Steeg et al, 1988) . The two tandemly arranged nm23 genes NMEJ and NME2 code for the proteins nm23H1 and nm23H2, which share sequence homology with nucleoside diphosphate kinase (NDPK)A and (NDPK)B respectively (Wallet et al, 1990; Gilles et al 1991; Stahl et al, 1991) .
Although nm23 possesses enzyme activity, both its precise function and the mechanism by which it participates in anti-metastatic protection is uncertain. Recent data have dissociated NDP kinase activity both from levels of nm23 message and from any antimetastatic effects (MacDonald et al, 1993) . Several biochemical activities have been proposed for the nm23 proteins that could have regulatory significance and these include: activation of G proteins, homology with GAP proteins, inhibition of myeloid differentiation, Revised 8 October 1996 Accepted 23 October 1996 Correspondence to: JA Royds signal transduction involving a reversible serine phosphorylation and transcriptional regulation of genes including c-myc .Teng et al, 1991; Okabe-Kado et al, 1992; McDonald et al, 1993; Postel et al, 1993; Urano et al, 1993) .
Loss of heterozygosity and reduced expression of nm23 has been associated with poor prognosis and increased incidence of metastases in many epithelial tumours, such as those of colon, breast, melanocytes and liver (Hennessy et al, 1991; Leone et al, 1991a; Nakayama et al, 1992; Royds et al, 1993 Royds et al, , 1994 . These findings are supported by results from experimental studies and in particular from transfections of nm23Hl into murine melanoma and human breast carcinoma cell lines. The resultant constitutive nm23 expression not only caused a reduction in the metastatic potential of the cells but also altered their response to growth factors (Steeg et al, 1988; Leone et al, 1991a Leone et al, , 1993a . However, the inverse relationship between nm23 expression and metastatic potential is by no means universal and other tumours, such as those of the thyroid and lung, do not show an inverse correlation (Higashiyama et al, 1992; Luo et al, 1993; Royds et al, 1994) . Moreover, in neuroblastoma, elevated levels of nm23 transcripts along with amplification and mutation of the nm23Hl gene were associated with advanced stages of the disease and poor patient survival (Hailat et al, 1991; Leone et al, 1993b) . Thus, the relationship between nm23 and metastatic potential may vary between different tumour types. Most studies to date have focused on carcinomas and very little is known about the significance of nm23 in tumours of mesenchymal origin. A positive correlation has been demonstrated, using Northern blotting, between NDPK alpha (nm23H2) and metastatic ability in rat osteosarcomas (Honoki et al, 1993) . In a recent report on nm23 expression in Ewing's sarcoma (Arye et al, 1995) , nm23HlI/NDPK-A expression was consistently high and nm23H2/NDPK-B expression, although weaker and variable, was considered to be of no prognostic significance for these aggressive and presumably neuroectodermal paedi- atric tumours. However, we are not aware of any previous study on nm23 gene expression in a wide range of sarcomas and in adult human sarcomas in particular. The present study was designed to determine the relationship, if any, between nm23 gene expression, tumour grade and metastasis in soft tissue sarcoma.
MATERIALS AND METHODS
Eighty-eight patients referred to The Royal Marsden Hospital, London, with previously untreated soft tissue sarcoma were entered into the study. These patients (aged 2-80 years) were followed for a minimum of 3 years from the time of diagnosis or until death. Tumours were assigned by one of us (CF) to one of three grades (high, intermediate or low) either by tumour type or according to a scoring system based upon the degree of necrosis, pleomorphism, cellularity and mitotic activity. The following tumours were all considered to be high grade: synovial sarcoma, rhabdomyosarcoma, extraskeletal osteosarcoma, Ewing's and peripheral neuroectodermal tumours. Primary histological diagnostic confirmation was by 'Trucut' or open excision biopsy.
Patients were divided into four groups according to tumour ...... The commonest histological types were malignant fibrous histiocytoma (MFH) (21), unclassified (19), liposarcoma (14) and synovial sarcoma (8). The remaining sarcomas were leiomyosarcoma (2), rhabdomyosarcoma (2), osteosarcoma (1), chondrosarcoma (3), haemangiopericytoma (1), Ewing's sarcoma (4), fibrosarcoma (5), epitheioid (3) and neural sheath tumour (5). Tumours occurred in all major sites -extremity (49), girdle (16), head and neck (10), trunk (9) and retroperitoneum (4). The diagnosis of metastasis was made clinically with or without further biopsy. Between one and three nm23 expression and prognosis in soft tissue sarcomas 1 197 MNST, malignant neural sheath tumour.
blocks of formalin-fixed paraffin-embedded tissue were obtained from the initial tumour specimen for each case. Sections (5 gm) were cut, dewaxed and stained using a 1:200 dilution of an immunopurified polyclonal antibody raised to the internal peptide 11 of nm23 (a gift from Dr P Steeg). After extensive washes in phosphate-buffered saline (PBS), the bound antibody was detected with a three-stage avidin-biotin-peroxidase complex technique using diaminobenzidine hydrochloride (DAB) as chromogen (Vector Laboratories, Peterborough, UK). Sections were lightly counterstained with haematoxylin. Omission of the primary antibody was performed as a negative control. The sections were graded from 1 to 4 according to the degree of staining, i.e. 1 (0-25%), 2 (25-50%), 3 (50-75%) and 4 (75-100%), of cells strongly positive. In keeping with the principles established in our studies on other tumours (Royds et al, 1993 (Royds et al, , 1994 , each case with multiple blocks was ascribed an overall score according to the lowest nm23 staining score obtained. Univariate and multivariate analyses were carried out to determine associations between metastasis, recurrence, death, nm23 staining and other prognostic factors. Analysis was carried out separately for four of the specific histological types MFH (n = 21), unclassified (n = 19), liposarcoma (n = 14) and synovial sarcoma (n = 8) for which the numbers were sufficiently large. 
RESULTS
The anti-nm23 antibody has been characterized previously and shown to give two bands size 17 and 18 kb on Western blot (Rosengard et al, 1989) . Based on amino acid sequences, antipeptide 11 nm23 antiserum may detect both nm23Hl and nm23H2. Staining for nm23 was predominately cytoplasmic but nuclear staining was seen in some sections (Figures 1-4) . Of the 88 patients in the study, 19 developed recurrent disease, 23 developed metastases and 38 died from their tumour. Tumour grade was the only significant prognostic factor for survival or metastasis on mulivariate analysis (relative risk of dying as a result of a highgrade tumour = 8.55, P < 0.0001) ( (Figure 5 , relative risk of comas that metastasized were, however, more likely to have nm23 th a nm23 score 3 tumour = 0.64). Furthermore, the three score 3 (69% of the metastatic variants scored 3), with only 25% with sarcomas that gave grade 1 staining (< 25% cells scoring 4. For the highly metastatic group of unclassified/synovial all developed metastases within a short period of time sarcomas, all six tumours (100%) with an nm23 expression score time of 266 days).
of 1 or 2 metastasized. The comparable figure for score 1 and 2 ;is of the individual types of sarcoma for the histological sarcomas as a whole is only 58%. This suggests that loss of nm23 ,H (n = 21), unclassified (n = 19), liposarcoma (n = 14) expression has occurred in a few cases of these more aggressive, vial sarcoma (n = 8) are shown in Table 3 . Unclassified and usually highly staining, sarcomas and is associated with vial sarcomas were highly metastatic with 24 out of 27 metastatic potential in every case. However, the significance of these variants producing metastases. In contrast, only 12 this is not certain as the numbers are small. (34%) of the MFH and liposarcomas were metastatic.
The liposarcomas studied seemed to behave differently as 8 out ;on of these two groups, one of high, the other of low of 14 tumours were score 4, but only one of these was high grade c potential, revealed that, although the average time to and metastasized. As there is an overall trend among sarcomas of s was much shorter for the highly metastatic unclassi-increasing frequency of metastasis with increasing nm23 expresvial group (297 days compared with 667 days), this sion and as high expression (score 4) of nm23 accompanies was negligible if only those tumours with staining metastatic potential in 60% of non-liposarcoma tumours, it does 4 were compared (355 days compared with 327 days). appear that human sarcomas behave similarly in the main to the rat the difference was maintained in the score 3 tumours osteoblastoma and human neuroblastoma in which increased compared with 819 days). The overall trend showed that expression is associated with aggressive disease and metastatic an increased likelihood of developing metastasis with potential (Hailat et al, 1991; Honoki et al, 1993; Leone et al, g nm23 scores, as seen from the fact that only 7% of 1993b) . This is in contrast to many carcinomas in which loss of sarcomas had an nm23 expression score of 1, 17.5% nm23 is associated with metastatic potential. However, the possi-2, 29.5% had score 3 and rising to 45% for score 4. This bility that loss of nm23 may occur as a late event in the progresalso shown by the individual histological sarcoma sion of some metastatic sarcomas cannot be ruled out. In fact, a except that the less aggressive MFH and liposarcomas similar dichotomy has been reported for colorectal adenocarcifewer score 4 tumours with metastatic potential (see nomas with strong expression of nm23H1 and H2 being associated The highly metastatic group (unclassified/synovial) with early stages of tumour progression and a loss of expression 5 out of 24 metastatic tumours that had lost nm23 expresseen in more advanced disease (Martinez et al, 1995) . re 1 or 2). Because of the small numbers involved, the
The finding that nm23 expression tends to increase as sarcomas Lce of this is uncertain. become more aggressive is perhaps not surprising as nm23 expression has been shown to be proportional to proliferation, growth ;SION factor receptor levels and expression of the signal transducing protein c-Ha-ras in many systems, including rat osteosarcomas it here nm23 tumour expression for a large cohort of 88 Keim et al, 1992; Honoki et al, 1993 are no longer required for cell cycle stimulation and control. This has been shown for ovarian carcinomas and breast tumours and cell lines that are oestrogen or progesterone receptor negative (Bevilacqua et al, 1989; Stahl et al, 1991; Mandai et al, 1994) . Thus, it could be postulated that, when growth factor stimulation of proliferation is high, it is accompanied by high expression of nm23 possibly because of its function in signal transduction and transcription of c-myc. This would explain why most at the score 4 metastatic sarcomas progressed very rapidly. In tumours in which cell proliferation becomes uncoupled from growth factor stimulation, then nm23 would no longer be necessary and its expression may be lost. Such tumours would also carry a poor prognosis by virtue of the fact that their proliferation is no longer limited by the availability of growth factors. This could be the case for the metastatic sarcomas that have low nm23 expression. In summary, increases in nm23 gene expression in sarcomas may signify a more active tumour which, if recurrent or metastatic, will progress rapidly. Although some sarcomas may lose nm23 expression as they progress, the level of nm23 expression carries no prognostic significance for sarcomas in general. Further work is planned in our laboratory to determine the prognostic value of nm23 loss in the more aggressive sarcoma variants and its possible association with an uncoupling from growth factor control. Additional evaluation of the differential effects of nm23H1 and H2 isoform expression in sarcomas and the possible loss of function of the nm23 because of the presence of mutation is also required.
